Albireo Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
130
- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
1
Albireo General Information
Description
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Contact Information
Website
www.albireopharma.comCorporate Office
- 53 State Street
- 19th Floor
- Boston, MA 02109
- United States
Corporate Office
- 53 State Street
- 19th Floor
- Boston, MA 02109
- United States
Albireo Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Albireo Comparisons
Industry
Financing
Details
Albireo Competitors (19)
One of Albireo’s 19 competitors is Mirum Pharmaceuticals, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals | Formerly VC-backed | Foster City, CA | ||||
| Evoke Pharma | Formerly VC-backed | Solana Beach, CA | ||||
| RedHill Biopharma | Formerly VC-backed | Raleigh, NC | ||||
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA |
Albireo Patents
Albireo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4836954-A1 | Benzothia(di)azepine compounds and their use as bile acid modulators | Pending | 05-Jan-2024 | ||
| EP-4836955-A1 | Benzothia(di)azepine compounds and their use as bile acid modulators | Pending | 05-Jan-2024 | ||
| WO-2025146507-A1 | Benzothia(di)azepine compounds and their use as bile acid modulators | Inactive | 05-Jan-2024 | ||
| WO-2025146508-A1 | Benzothia(di)azepine compounds and their use as bile acid modulators | Inactive | 05-Jan-2024 | ||
| AU-2024369988-A1 | Treating pfic2 with odevixibat | Pending | 03-Nov-2023 | A61K31/554 |
Albireo Signals
Albireo Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Albireo Acquisitions (1)
Albireo’s most recent deal was a Merger/Acquisition with Biodel for . The deal was made on 03-Nov-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biodel | 03-Nov-2016 | Merger/Acquisition | Drug Discovery |
Albireo FAQs
-
When was Albireo founded?
Albireo was founded in 2008.
-
Where is Albireo headquartered?
Albireo is headquartered in Boston, MA.
-
What is the size of Albireo?
Albireo has 130 total employees.
-
What industry is Albireo in?
Albireo’s primary industry is Drug Discovery.
-
Is Albireo a private or public company?
Albireo is a Private company.
-
What is the current valuation of Albireo?
The current valuation of Albireo is .
-
What is Albireo’s current revenue?
The current revenue for Albireo is .
-
How much funding has Albireo raised over time?
Albireo has raised $102M.
-
Who are Albireo’s investors?
Aberdeen Asset Management, Biodel, Decheng Capital, HBM Healthcare Investments, and Kreos Capital are 5 of 11 investors who have invested in Albireo.
-
Who are Albireo’s competitors?
Mirum Pharmaceuticals, Evoke Pharma, RedHill Biopharma, Crinetics Pharmaceuticals, and Ardelyx are some of the 19 competitors of Albireo.
-
When was Albireo acquired?
Albireo was acquired on 02-Mar-2023.
-
Who acquired Albireo?
Albireo was acquired by Ipsen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process